Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891723303> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2891723303 abstract "10113 Background: ADT is the most commonly used systemic therapy for treating locally advanced and metastatic PCa. ADT use causes hypogonadism, which can result in accelerated bone loss and fragility fractures. Vitamin D (VITD) may protect against bone loss; however it remains unclear if the recommended daily allowance (RDA) of VITD is sufficient to reduce bone loss or whether higher doses are needed. The aim of this phase II RCT was to collect preliminary data on the effect of high-dose VITD on bone mineral density (BMD) in ADT-treated PCa patients compared to the RDA of VITD. Methods: Older PCa patients (≥60 years old) with VITD insufficiency ( < 32 ng/ml), within 6 months of starting ADT and with 6 more planned months of ADT were randomized 1:1 to high-dose VITD (hVITD; 600 IU/daily plus 50,000 IU/weekly) or RDA of VITD (rVITD; 600 IU/daily plus placebo weekly) for 24 weeks. All subjects received 100% of the RDA for calcium (1,000 mg/day). BMD was assessed at the total hip (TH) and lumbar spine (LS) via DXA at pre- and post-intervention. ANCOVA was used to test the change in BMD between groups. Results: 59 PCa patients were accrued (85% white; mean age = 67.6). Serum analyses confirmed high compliance in both groups (25-OH VITD change: hVITD = +32.0 ng/ml vs rVITD = +4.3 ng/ml; p < 0.01). The safety of hVITD was similar to rVITD (Grade I hypercalcemia: hVITD: n = 1 vs rVITD: n = 0). Bone loss was significantly reduced for the hVITD group compared to rVITD group for total hip (TH BMD% change: hVITD = −1.5% vs rVITD = −4.1%; p = 0.02), with a trend for the femoral neck (BMD% change: hVITD = −1.7% vs rVITD = −4.3%; p = 0.06) and trochanter (BMD% change: hVITD = −1.0% vs rVITD = −2.8%; p = 0.10). There was no difference between groups for LS bone loss (LS BMD% change: hVITD = −0.8% vs rVITD = −0.6%; p = 0.75). Conclusions: High-dose VITD supplementation produced significantly greater reductions in hip BMD loss among older PCa patients receiving ADT compared to rVITD. Clinically, higher doses of VITD may be necessary to effectively prevent ADT-induced bone loss. A definitive phase III RCT is needed to confirm these findings. Funding: NCI R21CA175793, K07CA168911 & UG1CA189961. Bio-Tech Pharmacal Inc. supplied all agents. Clinical trial information: NCT02064946." @default.
- W2891723303 created "2018-09-27" @default.
- W2891723303 creator A5004242073 @default.
- W2891723303 creator A5014128456 @default.
- W2891723303 creator A5025793579 @default.
- W2891723303 creator A5038508194 @default.
- W2891723303 creator A5041853574 @default.
- W2891723303 creator A5048210530 @default.
- W2891723303 creator A5054306426 @default.
- W2891723303 creator A5060693199 @default.
- W2891723303 creator A5066562388 @default.
- W2891723303 creator A5069849278 @default.
- W2891723303 creator A5074254953 @default.
- W2891723303 creator A5079180398 @default.
- W2891723303 creator A5090040622 @default.
- W2891723303 creator A5090143035 @default.
- W2891723303 date "2017-05-20" @default.
- W2891723303 modified "2023-09-27" @default.
- W2891723303 title "A phase II RCT of high-dose vitamin D supplementation for androgen deprivation therapy (ADT)-induced bone loss among older prostate cancer (PCa) patients." @default.
- W2891723303 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.10113" @default.
- W2891723303 hasPublicationYear "2017" @default.
- W2891723303 type Work @default.
- W2891723303 sameAs 2891723303 @default.
- W2891723303 citedByCount "1" @default.
- W2891723303 countsByYear W28917233032020 @default.
- W2891723303 crossrefType "journal-article" @default.
- W2891723303 hasAuthorship W2891723303A5004242073 @default.
- W2891723303 hasAuthorship W2891723303A5014128456 @default.
- W2891723303 hasAuthorship W2891723303A5025793579 @default.
- W2891723303 hasAuthorship W2891723303A5038508194 @default.
- W2891723303 hasAuthorship W2891723303A5041853574 @default.
- W2891723303 hasAuthorship W2891723303A5048210530 @default.
- W2891723303 hasAuthorship W2891723303A5054306426 @default.
- W2891723303 hasAuthorship W2891723303A5060693199 @default.
- W2891723303 hasAuthorship W2891723303A5066562388 @default.
- W2891723303 hasAuthorship W2891723303A5069849278 @default.
- W2891723303 hasAuthorship W2891723303A5074254953 @default.
- W2891723303 hasAuthorship W2891723303A5079180398 @default.
- W2891723303 hasAuthorship W2891723303A5090040622 @default.
- W2891723303 hasAuthorship W2891723303A5090143035 @default.
- W2891723303 hasConcept C121608353 @default.
- W2891723303 hasConcept C124490489 @default.
- W2891723303 hasConcept C126322002 @default.
- W2891723303 hasConcept C126894567 @default.
- W2891723303 hasConcept C143998085 @default.
- W2891723303 hasConcept C168563851 @default.
- W2891723303 hasConcept C2776235491 @default.
- W2891723303 hasConcept C2777899217 @default.
- W2891723303 hasConcept C2777911890 @default.
- W2891723303 hasConcept C2780192828 @default.
- W2891723303 hasConcept C71315377 @default.
- W2891723303 hasConcept C71924100 @default.
- W2891723303 hasConceptScore W2891723303C121608353 @default.
- W2891723303 hasConceptScore W2891723303C124490489 @default.
- W2891723303 hasConceptScore W2891723303C126322002 @default.
- W2891723303 hasConceptScore W2891723303C126894567 @default.
- W2891723303 hasConceptScore W2891723303C143998085 @default.
- W2891723303 hasConceptScore W2891723303C168563851 @default.
- W2891723303 hasConceptScore W2891723303C2776235491 @default.
- W2891723303 hasConceptScore W2891723303C2777899217 @default.
- W2891723303 hasConceptScore W2891723303C2777911890 @default.
- W2891723303 hasConceptScore W2891723303C2780192828 @default.
- W2891723303 hasConceptScore W2891723303C71315377 @default.
- W2891723303 hasConceptScore W2891723303C71924100 @default.
- W2891723303 hasLocation W28917233031 @default.
- W2891723303 hasOpenAccess W2891723303 @default.
- W2891723303 hasPrimaryLocation W28917233031 @default.
- W2891723303 hasRelatedWork W1521108790 @default.
- W2891723303 hasRelatedWork W1732151415 @default.
- W2891723303 hasRelatedWork W2031270417 @default.
- W2891723303 hasRelatedWork W2055722076 @default.
- W2891723303 hasRelatedWork W2084535964 @default.
- W2891723303 hasRelatedWork W2180883751 @default.
- W2891723303 hasRelatedWork W2255853361 @default.
- W2891723303 hasRelatedWork W2282982569 @default.
- W2891723303 hasRelatedWork W2324715925 @default.
- W2891723303 hasRelatedWork W2603404971 @default.
- W2891723303 hasRelatedWork W2770449092 @default.
- W2891723303 hasRelatedWork W2811482540 @default.
- W2891723303 hasRelatedWork W2913942481 @default.
- W2891723303 hasRelatedWork W2947378988 @default.
- W2891723303 hasRelatedWork W3007684372 @default.
- W2891723303 hasRelatedWork W3007776535 @default.
- W2891723303 hasRelatedWork W3008251973 @default.
- W2891723303 hasRelatedWork W3031255026 @default.
- W2891723303 hasRelatedWork W3032600044 @default.
- W2891723303 hasRelatedWork W3049618992 @default.
- W2891723303 isParatext "false" @default.
- W2891723303 isRetracted "false" @default.
- W2891723303 magId "2891723303" @default.
- W2891723303 workType "article" @default.